CytomX Therapeutics, Inc. — Form 8-K
Filed July 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-07-27 reports Item 5.02 disclosure regarding departure of directors/officers and compensatory arrangements. Specific counterparties, dollar amounts, share counts, and detailed terms are not provided in the accessible filing header and metadata. Full substantive details require review of the complete 8-K document text.
Why this rating
Standard officer/director disclosure filing. Lacks specific dollar amounts or material transaction details relative to $372M company market cap to assess materiality.
Extracted items
See more from July 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.